Equities Analysts Set Expectations for AUTL FY2025 Earnings

Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) – Analysts at HC Wainwright issued their FY2025 EPS estimates for shares of Autolus Therapeutics in a report released on Tuesday, February 17th. HC Wainwright analyst E. Bodnar expects that the company will post earnings of ($1.04) per share for the year. HC Wainwright currently has a “Buy” rating and a $9.00 price objective on the stock. The consensus estimate for Autolus Therapeutics’ current full-year earnings is ($0.94) per share. HC Wainwright also issued estimates for Autolus Therapeutics’ Q4 2025 earnings at ($0.30) EPS, Q2 2026 earnings at ($0.28) EPS, Q3 2026 earnings at ($0.27) EPS, FY2027 earnings at ($0.83) EPS, FY2028 earnings at ($0.64) EPS and FY2030 earnings at ($0.24) EPS.

AUTL has been the subject of a number of other reports. Wall Street Zen lowered Autolus Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Saturday, November 15th. Zacks Research lowered Autolus Therapeutics from a “hold” rating to a “strong sell” rating in a report on Wednesday, January 21st. Needham & Company LLC lowered their target price on Autolus Therapeutics from $11.00 to $10.00 and set a “buy” rating on the stock in a report on Monday, January 12th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Autolus Therapeutics in a research report on Wednesday, January 21st. Five research analysts have rated the stock with a Buy rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $8.50.

Autolus Therapeutics Price Performance

NASDAQ AUTL opened at $1.51 on Wednesday. Autolus Therapeutics has a 12 month low of $1.11 and a 12 month high of $2.70. The firm has a market capitalization of $401.87 million, a PE ratio of -1.82 and a beta of 1.98. The company’s 50 day simple moving average is $1.57 and its 200 day simple moving average is $1.57.

Hedge Funds Weigh In On Autolus Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Independent Advisor Alliance purchased a new position in Autolus Therapeutics in the 4th quarter worth about $28,000. Marex Group plc purchased a new stake in Autolus Therapeutics during the second quarter valued at about $28,000. SmartHarvest Portfolios LLC acquired a new position in shares of Autolus Therapeutics in the fourth quarter worth about $43,000. Caitong International Asset Management Co. Ltd purchased a new position in shares of Autolus Therapeutics in the third quarter worth approximately $46,000. Finally, R Squared Ltd acquired a new stake in shares of Autolus Therapeutics during the second quarter valued at approximately $50,000. Institutional investors and hedge funds own 72.83% of the company’s stock.

Autolus Therapeutics Company Profile

Autolus Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of next-generation, programmed T cell therapies for the treatment of cancer. The company leverages proprietary technologies to engineer autologous T cells that target and eradicate tumor cells, with the aim of improving safety, efficacy and durability over existing cell therapies. Its R&D platform integrates antigen receptor design, gene editing and manufacturing optimization to generate candidates tailored for specific hematologic malignancies and solid tumor indications.

The company’s leading pipeline candidates include AUTO1, an optimized CD19-targeted CAR-T therapy for relapsed or refractory acute lymphoblastic leukemia, and AUTO3, a dual-targeted CD19/22 CAR-T program in development for diffuse large B-cell lymphoma.